Global Trend in Research and Development of CDK4/6 Inhibitors for Clinical Cancer Therapy: A Bibliometric Analysis.
Global Trend in Research and Development of CDK4/6 Inhibitors for Clinical Cancer Therapy: A Bibliometric Analysis.
复制标题
用于临床癌症治疗的 CDK4/6 抑制剂研发的全球趋势：文献计量分析
DOI：
10.7150/jca.51609
复制
发表时间：
2021
影响因子：
3.9
通讯作者：
Yao H
中科院分区：
文献类型：
--
作者：
Lai H;Jiang W;Zhao J;Dinglin X;Li Y;Li S;Wang Y;Yao H
背景：细胞周期蛋白依赖性激酶（CDK）4/6抑制剂是激素受体阳性乳腺癌常用的抗癌药物。这项研究评估了过去二十年来CDK 4/6抑制剂的研究和开发（R&D）过程中的出版物。方法：检索Web of Science（WOS）和PubMed数据库，以确定自2001年以来与CDK 4/6抑制剂研究相关的出版物。使用VOS Viewer软件分析共现关键词，对研究中的出版数据和合作进行分层。结果：2001年以来共收录CDK 4/6抑制剂相关文献1395篇。排名前十的机构中有八家来自美国，另外两家是瑞士制药公司和法国研究所。在美国发表的一些文章的第一作者Bardia A是最多产的，发表了25篇文章。发表文章最多的期刊是《癌症研究》，有162篇文章。基础研究包括10种最常被引用的出版物中的6种，其余包括3篇评论和1项临床试验。自2011年以来，最常见的出版物关键词是“palbociclib”、“abemaciclib”、“ribociclib”和“双盲”，表明CDK 4/6抑制剂作为抗癌药物的成功开发。结论：本研究对CDK 4/6抑制剂的研发历史进行了全面回顾。这些数据表明，该领域的药物开发是一个长达十年的过程，在临床应用之前已经进行了临床试验。此后，对与抑制剂相关的不良反应和耐药性进行了研究。
Background: Cyclin-dependent kinase (CDK) 4/6 inhibitors are frequently used anti-cancer agents in hormone receptor-positive breast cancers. This study assessed the course of research and development (R&D) for CDK4/6 inhibitors in terms of publications over the past two decades. Methods: The Web of Science (WOS) and PubMed databases were searched to identify publications related to research on CDK4/6 inhibitors since 2001. The VOS Viewer software was used to analyze co-occurring keywords to stratify the publication data and collaborations in research. Results: There were 1395 publications related to research on CDK4/6 inhibitors since 2001. Eight of the top 10 institutions originated from the USA and the other two were a Swiss Pharmaceutical Company and French Research Institute. Bardia A, the first author for some of the articles published in the USA, was the most prolific with 25 publications. The journal with the most publications was Cancer Res with 162 publications. Basic research comprised six of the 10 most frequently cited publications and the rest consisted of three reviews and a clinical trial. The most common keywords for publications since 2011 were “palbociclib”, “abemaciclib”, “ribociclib” and “double blind”, indicating the successful development of CDK4/6 inhibitors as anticancer drugs. Conclusions: This study provides a comprehensive review of the CDK4/6 inhibitors R&D history. The data imply that drug development in this field is a decade-long process and clinical trials have been performed before clinical applications. Thereafter, research was conducted on the adverse effects and drug resistance associated with the inhibitors.
登录
查看更多内容
影响因子：
11.2
作者：
Jacobson RS;Becich MJ;Bollag RJ;Chavan G;Corrigan J;Dhir R;Feldman MD;Gaudioso C;Legowski E;Maihle NJ;Mitchell K;Murphy M;Sakthivel M;Tseytlin E;Weaver J
通讯作者：
Weaver J
影响因子：
3.9
作者：
Miller, Todd W.;Traphagen, Nicole A.;Fadul, Camilo E.
通讯作者：
Fadul, Camilo E.
影响因子：
11.5
作者：
Geoerger, Birgit;Bourdeaut, Franck;Chi, Susan N.
通讯作者：
Chi, Susan N.
影响因子：
19
作者：
Goel S;DeCristo MJ;McAllister SS;Zhao JJ
通讯作者：
Zhao JJ
影响因子：
--
作者：
Chen, Dehong;Sun, Xiaosong;Cao, Jun
通讯作者：
Cao, Jun